Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival in Azacitidine-Treated Patients Assessed

Leuk Res; 2017 Oct 27; Sébert, Komrokji et al

Publish date:: November 19, 2017

People with myelodysplastic syndrome (MDS) who received azacytidine and achieved complete cytogenetic response (CCyR) experienced better overall survival than those who did not achieve such, according to a study involving >700 individuals. Participants had either higher risk MDS or low blast count acute myeloid leukemia, and included those with abnormal karyotype. Investigators looked at the prognostic impact of baseline cytogenetics and cytogenic response (CyR) on overall response and survival rates. In 281 evaluable patients with abnormal cytogenics:

CyR was achieved in ~one-third.
CCyR was attained in one-fourth.
CyR did not impact survival overall.
Those with MDS who achieved CCyR experienced better overall survival.

Citation:

Sébert M, Komrokji R, Sekeres M, et al. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leuk Res. 2017;63:72-77. doi:10.1016/j.leukres.2017.10.013.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release